So similar, yet so different: α-synuclein recognition of the isoform-specific VDAC protein-lipid interface
Tatiana K. RostovtsevaiD, Megha RajendraniD, William M. RosencransiD, María Queralt-MartíniD, Mya S. Wolfe, Nina A. Bautista, Bethel G. BeyeneiD, Motahareh Ghahari LarimiiD, Alexander J. SodtiD, Sergey M. BezrukoviD
Abstract
In mammals, VDAC exists as three isoforms--VDAC1, VDAC2, and VDAC3--each characterized by a distinct tissue-dependent distribution and physiologic role. Isoform-specific knockout studies in cells and mice demonstrate distinct physiological roles for each VDAC isoform. The isoforms share about 70% sequence homology and a conserved {beta}-barrel structure and, when reconstituted into planar lipid membranes, form similar highly conductive, anion-selective, voltage-gated channels. A natural question, then, is how relatively minor differences in isoform sequences lead to striking differences in their interactions with protein partners and, consequently, in their physiological functions. To address this question, we used a small, intrinsically disordered cytosolic protein -synuclein (Syn) as a sensitive molecular probe. A comparative study with recombinant VDACs reconstituted into planar lipid membranes shows that, depending on the isoform, the Syn-induced blockage exhibits up to 100-fold differences in on-rates and equilibrium constants. The isoforms also display distinct translocation regimes for Syn, as evidenced by altered dependences of the off-rates on the applied voltage. Deletion of cysteine residues has a significant effect on Syn binding. Combined with corresponding data obtained for VDAC2 substates--which show an order of magnitude variation in on-rates while maintaining the conserved equilibrium constants--and the results of molecular dynamics simulations, these findings point to a previously unrecognized step in VDAC inhibition by Syn: an isoform-specific Syn interaction with the VDAC protein-lipid interface. This finding opens a new paradigm for understanding VDAC isoform functions and developing isoform-specific therapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Conformational plasticity of mitochondrial VDAC2 controls the kinetics of its interaction with cytosolic proteins
William M. Rosencrans, Harisankar Khuntia, … Tatiana K. Rostovtseva·Science AdvancesPeer-reviewed·Apr 23, 2025
- α-Synuclein emerges as a potent regulator of VDAC-facilitated calcium transport
W. M. Rosencrans, V. M. Aguilella, … S. M. Bezrukov·bioRxiv·Nov 15, 2020
- Towards VDAC pharmacology: Developing small-peptide channel inhibitors inspired by nature
Tatiana K. Rostovtseva, Philip A. Gurnev, … Sergey M. Bezrukov·bioRxiv·Oct 19, 2026
- The intrinsically disordered N-terminus of the voltage-dependent anion channel
Jordane Preto, Isabelle Krimm·PLoS Computational BiologyPeer-reviewed·Feb 12, 2021
- Restricting α-Synuclein Transport into Mitochondria by Inhibition of α-Synuclein-VDAC Complexation as a Potential Therapeutic Target for Parkinson's Disease Treatment
M. Rajendran, M. Queralt-Martin, … T. K. Rostovtseva·bioRxiv·Apr 7, 2022
- A role for the V0 sector of the V-ATPase in neuroexocytosis: exogenous V0d blocks complexin and SNARE interactions with V0c
C. LEVEQUE, Y. MAULET, … O. EL FAR·bioRxiv·Jan 31, 2023